Glucagon like Peptide 1 News and Research

RSS

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes.

9 Apr 2014

New sweetener from tequila plant may aid diabetes, weight loss

A sweetener created from the plant used to make tequila could lower blood glucose levels for the 26 million Americans and others worldwide who have type 2 diabetes and help them and the obese lose weight, researchers said here today.

18 Mar 2014

Artificial sweetener sucralose has biological effects

The artificial sweetener sucralose is a biologically active compound according to an extensive review published by Taylor & Francis in the recent issue of Journal of Toxicology and Environmental Health, Part B: Critical Reviews. "Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues" authored by Susan S. Schiffman, PhD, an internationally known sweetener researcher and Kristina I. Rother, MD, MHSc, of the National Institutes of Health (NIH), summarizes the biological properties of sucralose based on hundreds of archival, peer-reviewed scientific journal publications.

13 Dec 2013

GLP-1 hormone can predict metabolic efficacy of gastric bypass

The sensitivity of the GLP-1 hormone, which is secreted by the gastrointestinal tract, can predict the metabolic efficacy of a gastric bypass. The use of a GLP1 challenge could thus function as a novel predictive biomarker for personalized treatment of type 2 diabetes and obesity.

8 Nov 2013

New therapeutic approach for treating type 2 diabetes

Scientists from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, have developed a new therapeutic approach for treatment of type 2 diabetes.

31 Oct 2013

Scientists develop new therapeutic approach for treatment of type 2 diabetes

Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.

31 Oct 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC stands for exchange protein activated by cyclic AMP (cAMP). cAMP is an (among many) intracellular messenger molecule. cAMP is generated when certain hormones stimulate a cell by binding to their receptor, which is at the outside surface of the cell.

3 May 2013

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Acute pancreatitis is an inflammation of the pancreas which leads to leakage of pancreatic enzymes. Apart from certain drugs such as GLP-1 based therapies, the most common causes of pancreatitis are Gallstones and Alcohol use.

30 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida.

28 Mar 2013

GLP1 medications appear to protect diabetic patients from heart failure

A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.

11 Mar 2013

GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.

28 Feb 2013

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.

25 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013